HC Wainwright reaffirmed their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a research note published on Tuesday, StockTargetPrices.com reports. HC Wainwright currently has a $5.00 target price on the stock.
Other equities research analysts also recently issued reports about the company. Maxim Group set a $2.00 target price on Bio-Path Holdings and gave the company a buy rating in a report on Wednesday, April 5th. Zacks Investment Research raised Bio-Path Holdings from a hold rating to a buy rating and set a $0.75 target price for the company in a report on Monday, March 20th.
Shares of Bio-Path Holdings (NASDAQ:BPTH) opened at 0.4001 on Tuesday. Bio-Path Holdings has a 52-week low of $0.33 and a 52-week high of $1.89. The stock’s market cap is $38.27 million. The company’s 50-day moving average price is $0.42 and its 200-day moving average price is $0.77.
Bio-Path Holdings (NASDAQ:BPTH) last announced its earnings results on Thursday, May 11th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. Analysts expect that Bio-Path Holdings will post ($0.07) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the first quarter valued at $105,000. HighTower Advisors LLC raised its position in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock valued at $1,043,000 after buying an additional 105,000 shares during the last quarter. Sabby Management LLC raised its position in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares during the last quarter. 19.88% of the stock is currently owned by hedge funds and other institutional investors.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285320/bio-path-holdings-inc-nasdaqbpth-given-buy-rating-at-hc-wainwright.html
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.